Brainomix’s e-Lung shows progression and treatment response in Phase III trial

Trial operators are increasingly incorporating imaging tools and related artificial intelligence (AI)-based tools into their study protocols. Trial operators are increasingly incorporating imaging into their study protocols. Brainomix’s e-Lung was proven sensitive to the effects of antifibrotic treatment. Credit: Marko Aliaksandr / Shutterstock.com. Brainomix has debuted data from a Phase III progressive pulmonary fibrosis (PPF) study that highlights the ability of its artificial intelligence (AI)-powered medical imaging tool, e-Lung, to predict a patient’s disease progression trajectory and assess how effectively they have responded to pharmaceutical treatment. According to analysis from the INBUILD study (NCT02999178), which evaluated the quantitative CT measurements…

Source: Medical Device Network